Self Assembly

Cima NanoTech developed the patented SANTE® Technology, a nanoparticle dispersion that self-assembles into a random mesh-like network pattern when coated onto substrates. This unique proprietary formula provides both outstanding electrical conductivity and excellent light transmission enabling transparent conductors for a multitude of applications like EMI shielding, transparent heating, touch, photovoltaic, OLED lighting and other flexible displays.

The CIC nanoGUNE Consolider, a newly established center in permanent pursuit of scientific excellence, with the mission and commitment to contributing to the competitive growth of the Basque Country, through the development of nanoscience and nanotechnology.

StoreDot is a company with a ground-breaking technology, based on its discovery of new generation, self-assembled Nanodots of biological origin. Representing elementary biological building blocks, these multifunctional Nanodots are at the core of several patented innovations by StoreDot, and constitute the future nanotechnology and advanced nano-photonic devices, including smartphones, TV’s, energy storage devices and more.

The main business field of PlasmaChem concerns nano-materials, detonation-, vacuum-, plasma- and ultra-thin film technologies and their biomedical and technical applications.

The main technology points of PlasmaChem concern the development of processes induced by low-temperature plasma on different surfaces and in organized mono-molecular films (Langmuir-Blodgett and Self-Assembly Films), in atomically flat inorganic solids and in liquid interfaces and advanced technologies of synthesis and modification of nano-materials.

Svaya brings molecular layer deposition to an industrial scale. We at Svaya believe that while molecular layer deposition has enabled many of the products that enrich our lives, including high definition displays, touch screens, dynamic windows and many more, the economic and capacity limitations have restricted adoption of this powerful technology. Svaya is fundamentally changing the tradeoff equation by deploying a breakthrough technology for molecular layer deposition that leverages the power of self-assembly for large area applications at industrial manufacturing speeds.

Focused on novel, nanotechnology-based therapeutics.

Cerulean Pharma Inc. is a clinical-stage biopharmaceutical company specializing in the design and development of nanopharmaceuticals. Cerulean’s nanopharmaceuticals are drug-containing nanoparticles designed and optimized to enhance efficacy and tolerability of therapeutic agents, ranging from small molecules to therapeutic peptides and RNAi molecules.

Cerulean is pursuing three key strategies:

Selecta Biosciences is a clinical-stage biotechnology company developing an entirely new class of targeted vaccines that induces an antigen-specific immune activation or antigen-specific immune tolerance for therapeutic and prophylactic applications.

Selecta's proprietary Synthetic Vaccine Particle (SVP™) platform creates a new paradigm in vaccine development, enabling completely new therapeutic applications with the potential for improved efficacy and safety profiles.